We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy (UpFrontPSMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04343885
Recruitment Status : Recruiting
First Posted : April 13, 2020
Last Update Posted : November 7, 2022
Movember Foundation
Prostate Cancer Research Alliance
United States Department of Defense
Advanced Accelerator Applications
Australian Nuclear Science and Technology Organisation (ANSTO)
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Australasian Radiopharmaceutical Trials network (ARTnet)
Centre for Biostatistics and Clinical Trials (BaCT)
Information provided by (Responsible Party):
Peter MacCallum Cancer Centre, Australia

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 2024
Estimated Study Completion Date : April 2024